Biosimilars are key alternatives for costly Biologics therapies and saving millions of dollars of patients in multiple diseases. Hence physicians are likely to adopt biosimilars “a reference product to biologics” […]readmore
Tags : Biocon Biologics
Shots: Biocon Biologics has acquired Pfizer’s 60,000 sq. ft state-of-the-art, bench to pilot scale R&D facility at TICEL Bio Park in Chennai, India The focus of the acquisition is to […]readmore